Intuniv, Tenex (guanfacine) is a small molecule pharmaceutical. Guanfacine was first approved as Intuniv on 1986-10-27. It is used to treat attention deficit disorder with hyperactivity and hypertension in the USA. It has been approved in Europe to treat attention deficit disorder with hyperactivity. It is known to target alpha-2B adrenergic receptor, alpha-2C adrenergic receptor, and alpha-2A adrenergic receptor. Guanfacine's patent is valid until 2022-07-04 (FDA).
|Indication||attention deficit disorder with hyperactivity, hypertension|
|Drug Class||Antihypertensives (guanidine derivatives)|